Imaging Features of Gadoxetic Acid-enhanced and Diffusion-weighted MR Imaging for Identifying Cytokeratin 19-positive Hepatocellular Carcinoma: A Retrospective Observational Study.

Radiology

From the Departments of Radiology (S.Y.C., J.E.L.) and Biomedical Statistics (B.R.L.), Soonchunhyang University College of Medicine, Bucheon Hospital, Gyeonggi-do, Korea; Department of Radiology and Center for Imaging Science (S.H.K., J.E.L.) and Department of Pathology (C.K.P.), Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Ilwon-Ro, Gangnam-gu, Seoul 06351, Korea; Department of Radiology, Chungnam National University Hospital, Chungnam National University College of Medicine, Daejeon, Korea (J.H.M.); and Department of Preventive Medicine, Gachon University Graduate School of Medicine, Incheon, Korea (Y.H.C.).

Published: March 2018

AI Article Synopsis

Article Abstract

Purpose To determine the preoperative magnetic resonance (MR) imaging findings potentially most useful for predicting cytokeratin 19 (CK19)-positive hepatocellular carcinoma (HCC) and to evaluate the prognosis after curative resection in patients with a single HCC lesion positive for CK19 compared with patients with HCC who are negative for CK19. Materials and Methods The institutional review board approved this study and waived the requirement for informed consent. Two hundred four patients with CK19-negative HCC and 38 with CK19-positive HCC who underwent curative resection after gadoxetic acid-enhanced and diffusion-weighted MR imaging were retrospectively evaluated in a single institution. Two radiologists evaluated preoperative findings at MR imaging. Significant findings for differentiating the two groups were identified at univariate and multivariate analyses. By using receiver operating characteristic analysis, the optimal cut-off values for quantitative variables were determined. Recurrence-free survival rates after surgery were also compared between groups. Results At multivariate analysis, irregular tumor margin (P = .024), arterial rim enhancement (P < .001), lower tumor-to-liver signal intensity (SI) ratio on hepatobiliary phase (HBP) images (≤0.522; P = .01), and lower tumor-to-liver apparent diffusion coefficient (ADC) ratio (≤0.820; P < .001) were independent significant factors to predict CK19-positive HCC. When three of these four criteria were combined, 63.2% (24 of 38; 95% confidence interval: 46.0%, 78.2%) of CK19-positive HCCs were identified with a specificity of 90.7% (185 of 204; 95% confidence interval: 46.0%, 78.2%). When all four criteria were satisfied, specificity was 99.5% (203 of 204; 95% confidence interval: 97.3%, 100%). Recurrence-free survival rates were significantly lower in patients with CK19-positive HCCs compared with those with CK19-negative HCCs after curative resection (63.9% vs 90.0% at 1 year, 63.9% vs 79.9% at 2 years, and 54.8% vs 70.2% at 3 years, P = .001 by log-rank test). Conclusion At gadoxetic acid-enhanced and diffusion-weighted MR imaging, irregular margin, arterial phase rim enhancement, lower tumor-to-liver ADC ratio, and lower tumor-to-liver SI ratio at HBP imaging may be helpful to predict CK19-positive HCC with early recurrence (<2 years) after curative resection. RSNA, 2017 Online supplemental material is available for this article.

Download full-text PDF

Source
http://dx.doi.org/10.1148/radiol.2017162846DOI Listing

Publication Analysis

Top Keywords

lower tumor-to-liver
16
gadoxetic acid-enhanced
12
acid-enhanced diffusion-weighted
12
diffusion-weighted imaging
12
curative resection
12
ck19-positive hcc
12
95% confidence
12
confidence interval
12
hepatocellular carcinoma
8
imaging findings
8

Similar Publications

Background: Accurately and promptly predicting the response of gastrointestinal stromal tumors (GISTs) to targeted therapy is essential for optimizing treatment strategies. However, some fractions of recurrent or metastatic GISTs present as non-FDG-avid lesions, limiting the value of [F]fluorodeoxyglucose positron emission tomography/computed tomography ([F]FDG PET/CT) in treatment evaluation. This study evaluated the efficacy of [F]F-fibroblast activation protein inhibitor (FAPI)-42 [F]FAPI-42) PET/CT for assessing the treatment response in recurrent or metastatic GISTs, in comparison to [F]FDG PET/CT and explores a model integrating PET/CT imaging and clinical parameters to optimize the clinical use of these diagnostic tools.

View Article and Find Full Text PDF

Quinazoline-2,4(1 H,3 H)-dione Scaffold for development of a novel PARP-targeting PET probe for tumor imaging.

Eur J Nucl Med Mol Imaging

November 2024

State Key Laboratory of Drug Research, Molecular Imaging Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.

Purpose: Overexpression of Poly (ADP-ribose) polymerase (PARP) is associated with many diseases such as oncological diseases. Several PARP-targeting radiotracers have been developed to detect tumor in recent years. Two F labelled probes based on Olaparib and Rucaparib molecular scaffolds have been evaluated in clinical trials, but their slow hepatic clearance hinders their tumor imaging performance.

View Article and Find Full Text PDF

Design, Synthesis, and Evaluation of [F]BIBD-300 as a Positron Emission Tomography Tracer for Poly(ADP-Ribose) Polymerase-1.

Mol Pharm

May 2024

Beijing Institute of Brain Disorders, Laboratory of Brain Disorders, Ministry of Science and Technology, Collaborative Innovation Center for Brain Disorders, Capital Medical University, Beijing 100069, China.

Article Synopsis
  • - Compounds were developed to enhance their ability to interact with PARP-1 by modifying their structure and lipophilicity. Assays showed that several compounds, especially [F]BIBD-300, displayed promising high-affinity properties worthy of further investigation.
  • - PET imaging indicated that [F]BIBD-300 showed lower nonspecific uptake and a better target-to-nontarget ratio compared to [F]FTT in both MCF-7 and 22Rv1 tumor models, suggesting it may be a more effective tracer for detecting PARP-1 in tumors.
  • - Unlike [F]FTT, which is primarily cleared through the liver, [F]BIBD-300 utilizes
View Article and Find Full Text PDF
Article Synopsis
  • This study explored the imaging characteristics of 2-Deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) PET/CT in patients with sacral chordoma compared to other sacral malignancies.
  • It found that sacral chordomas generally displayed minimal to moderate uptake in imaging, with a notably lower tumor-to-liver ratio (TLR) compared to other malignancies (median 2.1 vs. 6.3).
  • The TLR was identified as the most effective measure for distinguishing sacral chordoma from other cancers, showing high sensitivity and specificity in the analysis.
View Article and Find Full Text PDF

HER2 status determination is a necessary step for the proper choice of therapy and selection of patients for the targeted treatment of cancer. Targeted radiotracers such as radiolabeled DARPins provide a noninvasive and effective way for the molecular imaging of HER2 expression. This study aimed to evaluate tumor-targeting properties of three Tc-labeled DARPin G3 variants containing Gly-Gly-Gly-Cys (GC), (Gly-Gly-Gly-Ser)-Cys ((GS)C), or Glu-Glu-Glu-Cys (EC) amino acid linkers at the C-terminus and conjugated to the HYNIC chelating agent, as well as to compare them with the clinically evaluated DARPin G3 labeled with Tc(CO) using the (HE)-tag at the N-terminus.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!